Metronomic Cyclophosphamide with Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
Details
The purpose of this research study is to find out if the addition of oral cyclophosphamide to
intravenous pembrolizumab is able to improve the anti-tumor effect of pembrolizumab in patients
whose melanoma has continued to grow on checkpoint inhibitors alone.
Eligibility
You can join if...
Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help better understand eligibility in the study will be determined; the study team will go through the study eligibility criteria with the subject to verify if they qualify for participation in this study.
Inclusion Requirements
Subjects can participate in this study if you satisfy the following criteria:
At least 18 years of age
Confirmed diagnosis of Stage III or Stage IV non-ocular (not related to eye or eyesight) melanoma that cannot be removed with surgery (unresectable)
Must have received pembrolizumab or a similar PD-1 therapy within 6 weeks (every 3 week dosing) or 9 weeks (every 6 week dosing) prior to the first dose of the investigational therapy
Individuals who can become pregnant or partners of individuals who can become pregnant must be willing and able to use an adequate method of contraception to avoid pregnancy for the duration of the study.
Exclusion Requirements
You cannot participate in this study if you have any of the following criteria: